Deals in Depth: May 2010
Alliance leaders included GSK's €73.9 million investment in new partner Dong-A Pharmaceutical and Medtronic's $70 million investment in cardiovascular device company BioControl. Abbott led biopharma M&A activity with its $3.7 billion purchase of Piramal's healthcare solutions business. In devices, Endo paid $221 million up front for HealthTronics. Roughly 30 percent of the month's $953 million in biopharma fundraising came from Salix's $291 million debt deal. No public device dollars were realized in May, though 11 companies completed venture rounds.
You may also be interested in...
Medtech Insight sat down with Think Surgical’s CFO Paul Weiner at the recent AAOS conference to discuss the roll-out of the next-generation TSolution One TKA robot and company plans.
The US agency issued a letter to providers in the wake of a study that found significantly higher complication rates in women implanted with Boston Scientific’s Watchman device.
The company, which has reported no R&D successes outside of its CGRP inhibitor platform, said verdiperstat did not differentiate from placebo on any endpoints in multiple system atrophy.